Challenges in Permeability Assessment for Oral Drug Product Development
Mirko Koziolek,
Patrick Augustijns,
Constantin Berger,
Rodrigo Cristofoletti,
David Dahlgren,
Janneke Keemink,
Pär Matsson,
Fiona McCartney,
Marco Metzger,
Mario Mezler,
Janis Niessen,
James E. Polli,
Maria Vertzoni,
Werner Weitschies,
Jennifer Dressman
Affiliations
Mirko Koziolek
NCE Drug Product Development, Development Sciences, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany
Patrick Augustijns
Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium
Constantin Berger
Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070 Würzburg, Germany
Rodrigo Cristofoletti
Department of Pharmaceutics, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA
David Dahlgren
Department of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, Sweden
Janneke Keemink
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, 4070 Basel, Switzerland
Pär Matsson
Department of Pharmacology and SciLifeLab Gothenburg, University of Gothenburg, 40530 Gothenburg, Sweden
Fiona McCartney
School of Veterinary Medicine, University College Dublin, D04 V1W8 Dublin, Ireland
Marco Metzger
Translational Center for Regenerative Therapies (TLZ-RT) Würzburg, Branch of the Fraunhofer Institute for Silicate Research (ISC), 97082 Würzburg, Germany
Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed.